HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
N(6)- cyclopropyl- 9- (2- phosphonylmethoxyethyl)- 2,6- diaminopurine
structure in first source
Also Known As:
N(6)-cyclopropyl-PMEDAP; cPr-PMEDAP
Networked:
3
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Purines: 651
Adenine: 2120
N(6)-cyclopropyl-9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine: 3
Organic Chemicals: 133
Organophosphorus Compounds: 300
Organophosphonates: 424
N(6)-cyclopropyl-9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine: 3
Related Diseases
1.
Neoplasms (Cancer)
07/15/1999 - "
Our data demonstrate the superior antiproliferative and differentiation-inducing effects of cPr-PMEDAP on tumor cells, as compared to the parent compound PMEDAP, based on the unique metabolic properties of this novel compound.
"
01/01/1999 - "
Based on its efficacy and therapeutic safety, cPr-PMEDAP can be regarded as a promising antitumor agent, which merits further in vivo evaluation in additional tumor models for human neoplasms.
"
01/01/1999 - "
Also, whereas PMEG was unable to produce a prolonged antitumor effect, the animals treated with cPr-PMEDAP still showed prominent inhibition of tumor development when tumor size was evaluated at 2 weeks after end of treatment.
"
01/01/1999 - "
When compared at the maximum tolerated (sublethal) doses (i.e., 0.5, 10, and 50 mg/kg for PMEG, cPr-PMEDAP, and PMEDAP, respectively), cPr-PMEDAP proved superior to PMEG and PMEDAP in achieving a complete inhibition of tumor development.
"
01/01/1999 - "
Complete inhibition of choriocarcinoma tumor development was achieved upon treatment with cPr-PMEDAP, PMEG, and PMEDAP at a daily dose of 10, 1, and 50 mg/kg, respectively.
"
2.
Choriocarcinoma
07/15/1999 - "
Also, cPr-PMEDAP and PMEG proved to be equipotent inducers of K562 and rat choriocarcinoma RCHO cell differentiation, whereas the differentiation-inducing activity of PMEDAP was 5- to 25-fold less pronounced.
"
01/01/1999 - "
Complete inhibition of choriocarcinoma tumor development was achieved upon treatment with cPr-PMEDAP, PMEG, and PMEDAP at a daily dose of 10, 1, and 50 mg/kg, respectively.
"
01/01/1999 - "
We compared the in vivo antitumor efficacy and selectivity of cPr-PMEDAP, its progenitor PMEDAP, and PMEG in a rat choriocarcinoma tumor model.
"
3.
Leukemia L1210
07/15/1999 - "
Unlike PMEDAP, but like PMEG, cPr-PMEDAP was equally cytostatic to wild-type and 9-(2-phosphonylmethoxyethyl)adenine/PMEDAP-resistant variants of the human erythroleukemia K562 and the murine leukemia L1210 cell lines.
"
4.
Acute Erythroblastic Leukemia (Erythroleukemia)
07/15/1999 - "
Unlike PMEDAP, but like PMEG, cPr-PMEDAP was equally cytostatic to wild-type and 9-(2-phosphonylmethoxyethyl)adenine/PMEDAP-resistant variants of the human erythroleukemia K562 and the murine leukemia L1210 cell lines.
"
5.
Carcinoma (Carcinomatosis)
01/01/1998 - "
We have evaluated the effects of various ANPs [i.e., 3-hydroxy-2-phosphonylmethoxypropyl derivatives of adenine (HPMPA) and cytosine (HPMPC, cidofovir)]; cyclic HPMPC (cHPMPC); 9-(2-phosphonylmethoxyethyl) derivatives of adenine (PMEA, adefovir), guanine (PMEG), and 2,6-diaminopurine (PMEDAP); and cyclo-propyl PMEDAP (cPr-PMEDAP), several other antiviral drugs [i.e., acyclovir (ACV), ganciclovir (GCV), foscarnet (PFA), and ribavirin]; the antitumor agents cytarabine (AraC) and 5-fluorouracil (5-FU); and the immunosuppressant mycophenolic acid (MPA) on the proliferation of human cervical keratinocytes immortalized by HPV-33 (CK-1 cells) and the cervical carcinoma cell lines containing HPV-16 (CaSki and SiHa) or HPV-18 (HeLa).
"
Related Drugs and Biologics
1.
9-((2-phosphonylmethoxy)ethyl)guanine
2.
9- (2- phosphonylmethoxyethyl)- 2,6- diaminopurine
3.
Antineoplastic Agents (Antineoplastics)
4.
Adenine
5.
Cytostatic Agents
6.
Foscarnet
7.
Ganciclovir (Cytovene)
8.
Ribavirin (Virazole)
9.
Mycophenolic Acid (Cellcept)
10.
Immunosuppressive Agents (Immunosuppressants)